ArticleJournal of advanced research2026
Longitudinal prediction of drug response in high-grade serous ovarian cancer organoid cultures aligning with clinical responses.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Context-dependent roles of HtrA2/Omi in ovarian cancer: mitochondrial apoptotic function linking platinum sensitivity and acquired chemoresistance-a narrative review.Translational cancer research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHigh-grade serous ovarian cancer (HGSOC) ranks among the most aggressive gynecological malignancies. Its high mortality is driven by frequent recurrence after primary treatments and the development of platinum resistance. Traditional drug development using animal models is time-consuming and often lacks reproducibility, making it less effective for precision cancer medicine.
objectivesThis study aimed to demonstrate the potential of primary patient-derived tumor organoids (PDTOs) as a platform to replicate disease pathophysiology and accelerate drug screening for HGSOC. The focus was on validating the stability of PDTOs in predicting drug responses over time and comparing in vitro results with clinical data.
methodsAn expandable HGSOC PDTO platform was developed for rapid drug screening and resistance testing. Seven pairs of organoids underwent low- and high-passage drug screenings over up to a nine-month period. The screenings involved 20 conventional and FDA-approved drugs, and proteomic analyses were conducted to assess the stability of the organoids over time.
resultsThe comparison of in vitro drug screening outcomes with clinical data confirmed the predictive capacity of the organoid platform. Notably, a PDTO with a BRCA1 mutation exhibited resistance to Carboplatin and PARP inhibitors, reflecting the clinical scenario and reinforcing the platform's predictive power.
conclusionThis study underscores the clinical significance of organoid models in predicting drug resistance and therapeutic response. These models demonstrated their utility in screening novel treatments, such as Peptidylprolyl Cis/Trans Isomerase, NIMA-Interacting 1 (Pin1) inhibitors, which show potential in overcoming resistance to standard ovarian cancer therapies. The organoid platform offers a powerful tool for advancing personalized treatment approaches, with the capability to guide therapeutic decisions and optimize patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.